A Propensity Score-Matched Study on the Changes of TB Status and TB-IGRA Values in Patients with Psoriasis with Latent TB Receiving Secukinumab.

Yue XiaoWenyao MiJinqiu WangDingke WenYiyi WangYuanxia GuDan HaoWei YanXuerong ChenWei Li

Published in: Dermatology and therapy (2023)

Our data provide additional information on the safety profile of secukinumab in patients with psoriasis with LTBI. Furthermore, our presentation of the reexamined IGRA results revealed no significant elevation in the ATB or NTB group. As such, we believe further exploration is necessary to determine whether anti-TB medication is required prior to administering secukinumab.

Keyphrases

mycobacterium tuberculosis
ankylosing spondylitis
healthcare
single cell
emergency department
case report
atopic dermatitis
health information
disease activity
adverse drug